4 months ago
SYRE
AnalystsAlex ThompsonAlex Thompson's Stock Forecasts
AnalystsAlex Thompson
Sectors:
Industries:
Analyst Ranking
Top 8%
#410 out of 5326 analysts
Average Return
+26.11%
Win Rate
65%30 out of 46
Risk vs Reward
Poor
Good
Alex Thompson's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Dianthus Therapeutics IncDNTH | +184.18% | $37.16 | $105.60 | 2025-09-12 - 2026-07-17 | Strong Buy |
Kymera Therapeutics IncKYMR | +148.54% | $31.44 | $78.14 | 2025-05-20 - 2026-05-19 | Strong Buy |
Spyre Therapeutics IncSYRE | +132.77% | $43.06 | $100.23 | 2026-03-18 - 2026-07-17 | Strong Buy |
Oruka Therapeutics IncORKA | +131.75% | $40.00 | $92.70 | 2026-03-13 - 2026-07-17 | Strong Buy |
Dice Therapeutics IncDICE | +126.21% | $21.02 | $47.55 | 2022-09-07 - 2023-08-08 | Strong Buy |
Alex Thompson Analyst Color
Get additional color on Alex Thompson's coverage of popular stocks
4 months ago
ORKA
4 months ago
ANAB
7 months ago
ASND
7 months ago
ARGX
9 months ago
ANAB
10 months ago
DNTH
2 years ago
ASND
2 years ago
ARGX
2 years ago
SYRE
3 years ago
SYRE
3 years ago
ACRS
3 years ago
IMVT
4 years ago
ARGX
4 years ago
KDNY
Alex Thompson's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Spyre Therapeutics IncSYRE | 5 | Strong Buy | $107.00 | +6.75% | Maintains | 2 months ago |
Oruka Therapeutics IncORKA | 2 | Strong Buy | $72.00 | -22.33% | Maintains | 4 months ago |
Anaptysbio IncANAB | 3 | Strong Buy | $85.00 | +46.55% | Maintains | 4 months ago |
Celldex Therapeutics IncCLDX | 1 | Strong Buy | $68.00 | +92.36% | Reiterates | 5 months ago |
Alumis IncALMS | 1 | Strong Buy | $44.00 | +53.52% | Initiates Coverage On | 5 months ago |
Palisade Bio IncPALI | 1 | Strong Buy | $5.00 | +153.81% | Initiates Coverage On | 5 months ago |
Ascendis Pharma AASND | 4 | Strong Buy | $256.00 | -1.92% | Maintains | 7 months ago |
Argenx SeARGX | 5 | Strong Buy | $1,248.00 | +45.02% | Maintains | 7 months ago |
Dianthus Therapeutics IncDNTH | 2 | Strong Buy | $65.00 | -38.45% | Maintains | 10 months ago |
Travere Therapeutics IncTVTX | 4 | Hold | $25.00 | -55.92% | Maintains | 10 months ago |
Cullinan Therapeutics IncCGEM | 1 | Strong Buy | $22.00 | N/A | Reinstates | a year ago |
Kymera Therapeutics IncKYMR | 1 | Strong Buy | $55.00 | N/A | Reinstates | a year ago |
Third Harmonic Bio IncTHRD | 2 | Hold | $5.00 | N/A | Downgrades | a year ago |
Avalo Therapeutics IncAVTX | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | a year ago |
Crinetics Pharmaceuticals IncCRNX | 1 | Strong Buy | $60.00 | N/A | Initiates Coverage On | a year ago |
Morphic Holding IncMORF | 4 | Hold | $57.00 | N/A | Maintains | 2 years ago |
Ventyx Biosciences IncVTYX | 5 | Hold | $2.00 | N/A | Maintains | 3 years ago |
Moonlake ImmunotherapeuticsMLTX | 2 | Strong Buy | $69.00 | N/A | Maintains | 3 years ago |
Aclaris Therapeutics IncACRS | 4 | Hold | $1.00 | N/A | Maintains | 3 years ago |
Viridian Therapeutics IncVRDN | 2 | Strong Buy | $40.00 | N/A | Reiterates | 3 years ago |
Rapt Therapeutics IncRAPT | 1 | Strong Buy | $320.00 | N/A | Initiates Coverage On | 3 years ago |
Immunovant IncIMVT | 2 | Strong Buy | $34.00 | N/A | Maintains | 3 years ago |
Chinook Therapeutics IncKDNY | 3 | Hold | $41.00 | N/A | Downgrades | 3 years ago |
Pliant Therapeutics IncPLRX | 1 | Strong Buy | $33.00 | N/A | Initiates Coverage On | 4 years ago |
Dice Therapeutics IncDICE | 1 | Strong Buy | $37.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.